Pharmacodynamics Evaluation of PhaseBio’s Novel Ticagrelor Reversal Agent Presented at ESC Congress 2019
PhaseBio Pharmaceuticals, Inc. (PHAS)
Last phasebio pharmaceuticals, inc. earnings: 3/30 08:01 am
Check Earnings Report
Company Research
Source: GlobeNewswire
MALVERN, Pa. and SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that data from an evaluation of the pharmacodynamics of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, were presented by Lisa K. Jennings, Ph.D., Professor of Medicine, University of Tennessee Health Science Center, at ESC Congress 2019 in Paris on September 1. “Utilizing multiple assays of platelet function provided a wider range of understanding of the pharmacodynamics of PB2452 in the first-in-human clinical trial,” said Dr. Jennings. “PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet activity, which could reduce the bleeding risk associated with ticagrelor. The Phase 1 data support further evaluation of PB2452 for the reversal of the antiplatelet effects of ticagrelor in emerge
Show less
Read more
Impact Snapshot
Event Time:
PHAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAS alerts
High impacting PhaseBio Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics